Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical's VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
Catalyst Pharmaceuticals(CPRX) Newsfilter·2024-02-21 22:00Catalyst Pharmaceuticals, Inc.研究结果 - Vamorolone是一种选择性结合糖皮质激素受体的解离性皮质类固醇，与杜兴氏肌营养不良（DMD）中的泼尼松相比，显示出类似的疗效和减少的安全性问题[2] - Vamorolone在6mg/kg/d剂量下显示出对所有运动结果的改善维持，而在2mg/kg/d剂量下显示出与6mg/kg/d剂量相似的改善[3] - AGAMREE®（vamorolone）口服悬浮液40mg/ml已获得美国DMD治疗的商业化批准[5]